France's Advicenne SA, a biopharmaceutical company developing therapies for orphan diseases, is planning a secondary listing on the Euronext Brussels stock exchange.
The company's ordinary shares are currently listed on the Euronext Paris stock exchange and would be cross listed on the Euronext Brussels if the proposed listing is approved. Euronext Paris will remain as the company's primary listing venue.
The cross listing will increase the visibility of Advicenne's shares in Belgium and beyond, the company said in a news release. Advicenne is conducting a phase 2/3 study of its lead product ADV7103 in Belgium for treating cystinuria, a rare kidney disease.
The cross listing would have no impact on Advicenne's current shareholders.